Previous 10 | Next 10 |
Evotec ( NASDAQ: EVO ) and Johnson & Johnson ( NYSE: JNJ ) signed a collaboration and license agreement to develop first-in-class targeted immune-based therapies for cancer. J&J's unit Janssen Biotech entered the collaboration with Germany's Evotec ...
STRATEGIC PARTNERSHIP LEVERAGES EVOTEC'S EXPERTISE & INTEGRATED PLATFORM FOR DISCOVERY AND DEVELOPMENT HAMBURG, GERMANY / ACCESSWIRE / January 26, 2023 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) announced today that the Company has entered in...
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization to treat patients with Type 1 Diabetes (T1D) and severe hypoglycemia iPSC islet-like cluster manufacturing scale-up and te...
Summary The Seeking Alpha Quant system has its quirks, but it is a great tool to find holdings. I will discuss the performance of the five holdings I covered in the prior article. Also, at the end, I will provide some interesting literature discussing the Seeking Alpha platform as a...
THE COLLABORATION ADDS TWO DRUG DISCOVERY PROJECTS TO THE PORTFOLIO AND DESIGNATES A TARGET-BASED PROGRAMME FOR DEVELOPMENT EVOTEC RECEIVES PAYMENTS IN TOTAL OF US$ 26 M FROM BRISTOL MYERS SQUIBB HAMBURG, GERMANY / ACCESSWIRE / December 16, 2022 / Evotec SE (Frankfurt Stock Exchange: E...
Evotec SE (EVOTF) Q3 2022 Results Conference Call November 09, 2022 08:00 AM ET Company Participants Werner Lanthaler - Chief Executive Officer Enno Spillner - Chief Financial Officer Craig Johnstone - Chief Operating Officer Cord Dohrmann - Chief Scientific ...
MULTIPLE NEW AND EXTENDED ALLIANCES IN ALL AREAS PARADIGM SHIFT IN BIOLOGICS STARTING ITS MARKET ENTRY STRATEGY COMMERCIAL LAUNCH OF NEXT-GENERATION MULTI-OMICS DATA ANALYSIS PLATFORM PANHUNTER HAMBURG, GERMANY / ACCESSWIRE / November 9, 2022 / Evotec SE (Frankfurt Stock Exc...
HAMBURG, GERMANY / ACCESSWIRE / November 3, 2022 / Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) will announce its financial results for the first nine months 2022 on Wednesday, 09 November 2022. The Company is going to hold a conference call to discu...
AS EVOTEC DRUG SUBSTANCE (GERMANY) GMBH, THE ACQUISITION STRENGTHENS EVOTEC'S CLINICAL AND COMMERCIAL DRUG SUBSTANCE MANUFACTURING CAPACITY AND CAPABILITY ESPECIALLY FOR RARE DISEASES AND PRECISION THERAPEUTICS HAMBURG, GERMANY / ACCESSWIRE / November 3, 2022 / Evotec SE (Frankfurt St...
TOGETHER FOR MEDICINES THAT MATTER: A PARADIGM SHIFT TO UNLOCK NEW MARKETS AND OPPORTUNITIES FOR GLOBAL ACCESS TO BIOLOGICS BY APPLYING A FULLY INTEGRATED, END-TO-END CONTINUOUS BIOMANUFACTURING PROCESS JUST - EVOTEC BIOLOGICS SELECTED FOR A SECOND AWARD UNDER THE US DEPARTMENT OF DEFE...
News, Short Squeeze, Breakout and More Instantly...
Multi-year collaboration will initially focus on early discovery research for metabolic and infectious diseases HAMBURG, GERMANY / ACCESSWIRE / July 10, 2024 / Evotec SE (Frankfurt Stock Exchange:EVT)(NASDAQ:EVO) (MDAX/TecDAX , ISIN: DE0005664809) today announced it has entered into a mul...
Just - Evotec Biologics expands partnership with Sandoz for development and commercial manufacturing of biosimilars Additional biosimilars potentially to be added to Sandoz development pipeline Further guarantees for Sandoz long-term commercial supply security HAMBURG, GERMANY...
Just - Evotec Biologics will deliver an ultra-rapid, cost-efficient biotherapeutics manufacturing platform solution for the DOD's Manufacturing Optimization Program Manufacturing solution includes seamless integration of accelerated mAb drug development into the overall Manufacturing Optimiz...